Bundesamt für Verbraucherschutz und Lebensmittelsicherheit

Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL)
Federal Office of Consumer Protection and Food Safety
Mauerstraße 39-42
10117 Berlin
(Germany)

DRAFT

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Stenorol Crypto 0.5 mg/ml oral solution for calves

Date: 3 June 2020

"This product was originally authorised under an EU procedure prior to 1st January 2021 where the UK participated as a Concerned Member State. Therefore, the contents of this Public Assessment Report are not owned by the Veterinary Medicines Directorate. Please contact the original Reference Member State for any queries in relation to this report."

MODULE 1

PRODUCT SUMMARY

EU Procedure number	DE/V/0329/001/DC
Name, strength and pharmaceutical form	Stenorol Crypto 0.5 mg/ml oral solution for calves
Applicant	HUVEPHARMA NV Uitbreidingstraat 80 2600 Antwerpen Belgium
Active substance(s)	Halofuginone
ATC Vetcode	QP51AX08
Target species	Cattle (Newborn calves)
Indication for use	In newborn calves: Prevention of diarrhoea due to diagnosed Cryptosporidium parvum, in farms with history of cryptosporidiosis. Administration should start in the first 24 to 48 hours of age. Reduction of diarrhea due to diagnosed Cryptosporidium parvum. Administration should start within 24 hours after the onset of diarrhoea. In both cases, the reduction of oocysts excretion has been demonstrated.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicinal Agencies website (www.hma.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Application in accordance with Article 13 (1) of Directive 2001/82/EC as amended.
Date of completion of the original Decentralised procedure	03 June 2020
Date product first authorised in the Reference Member State (MRP only)	n.a.
Concerned Member States for original procedure	AT; BE; BG; CY; CZ; DK; EE; ES; FR; HU; HR; IE; IT; LT; LU; LV; MT; NL; PL; PT; RO; SI; SK; UK

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species. Information on adverse effects and proper use are adequately indicated in the SPC.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The safety and efficacy aspects of this product are identical to the reference product HALOCUR 0.5 mg/ml oral solution for calves, which has been authorised in 1999 *via* a centralised procedure.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The product contains 0.50 mg/ml halofuginone (as lactate) as active substance and the excipients benzoic acid, tartrazine, lactic acid and water for injections.

The product is packaged in white cylindrical high density polyethylene (HDPE) bottles closed with a white tamper-evident screw closure. Two package sizes are available: 500 mL and 1 L.

The choice of the formulation and the presence of preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

The product is manufactured in accordance with the European Pharmacopoeia and relevant European guidelines.

C. Control of Starting Materials

The active substance is halofuginone lactate an established active substance. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D. Control on intermediate products

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

The claim of a 1 month stability after broaching is based on the demonstration of stability for a batch broached and stored 1 month at 25 °C.

G. Other Information

Not applicable.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

For generics, insert in the relevant sections as appropriate:

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmacological and toxicological tests are not required.

The safety aspects of this product are identical to the reference product.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

Phase I:

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the initial predicted environmental concentration in soil (PECsoil,initial = 4.0 µg/kg) is less than 100 µg/kg.
It can be expected that HALOFUR 0.5 mg/ml oral solution for calves will not pose a risk to the environment when used in accordance with the SPC.

III.B Residues documentation

Residue Studies

No residue depletion studies were conducted as this is a generic application according to Article 13 (1) of Directive 2001/82/EC, and bioequivalence with a reference product has been accepted according to exemption 7.1. c) of the Guideline on the conduct of bioequivalence studies for veterinary medicinal products (EMA/CVMP/016/00-Rev.2.). Therefore, residue depletion studies are not required and the withdrawal period suggested by the applicant is considered sufficient to ensure consumer safety.

MRLs

Halofuginone is included in Table 1 of the Annex to Commission Regulation (EU) No 37/2010 as follows:

Pharmacologically active Substance	Marker residue	Animal Species	MRL	Target Tissues	Other Provisions	Therapeutic Classification
Halofuginone	Halofuginone	Bovine	10 µg/kg 25 µg/kg	Muscle Fat Liver Kidney	Not for use in animals from which milk is produced for	Antiparasitic agents/Agents acting against protozoa

			30 μg/kg 30 μg/kg		human consumption.	

Withdrawal Periods

Based on the nature of the application and the information provided, a withdrawal period of 13 days for meat and offal in calves is justified.

IV. CLINICAL ASSESSMENT (EFFICACY)

This is a generic application according to Article 13 (1) of Directive 2001/82/EC, and bioequivalence with a reference product has been accepted according to exemption 7.1. c) of the Guideline on the conduct of bioequivalence studies for veterinary medicinal products (EMA/CVMP/016/00-Rev.2.). Therefore, efficacy studies are not required and efficacy claims identical to the reference product are accepted.

IV.A Pre-Clinical Studies

As this is a generic application according to Article 13 (1) of Directive 2001/82/EC, and bioequivalence with a reference product has been accepted, provision of preclinical data was not required. With the exception of minor editorial amendments, the information on pharmacodynamics, pharmacokinetics as well as contraindications and precautions are in line with the product information given for the reference product. The target animal safety aspects are considered to be identical to the reference product.

IV.B Clinical Studies

As this is a generic application according to Article 13 (1) of Directive 2001/82/EC, and bioequivalence with a reference product has been accepted, provision of clinical data was not required. The efficacy claims are equivalent to those of the reference product.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Veterinary Medicinal Agencies website (www.hma.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

None